[The effect of inhaling pirenzepine--selective M1 receptor antagonist and ipratropium bromide on lung ventilation in patients with bronchial asthma].
The study was carried out on 19 patients with moderate and severe bronchial asthma. During three days after the initial spirometric evaluation the patients received--on the first day 0.5 mg of pirenzepine in nebulization (P), on the second day 0.25 mg of ipratropium bromide (IB), on the third day both substances together. Ventilatory parameters were monitored on the 5th, 20th, 40th and 60th minute following nebulization. The observed parameters did not differ significantly between both groups. Pirenzepine given after ipratropium bromide increased FEV1 from 1.89 L to 2.37 L (p < 0.01). The observed results imply that pirenzepine given with ipratropium bromide induce a significant bronchodilating effect and could be added to therapy of bronchial asthma.
Krasnowska
M
M
Katedry i Kliniki Chorób Wewnetrznych i Alergologii AM we Wrocławiu.
Jankowska
R
R
Jagiełło
E
E
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D016084:Bronchoconstriction / Q000187:drug effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010890:Pirenzepine / Q000008:administration & dosage*; D015656:Respiratory Mechanics / Q000187:drug effects
D010890:Pirenzepine; D009241:Ipratropium
Wpływ inhalacji pirenzepiny-wybiórczego antagonisty receptorów M1 i ipratropium bromide na wentylacje płuc u chorych na dychawice oskrzelowa.